title: Advances in methodology and current prospects for primary drug therapies for Alzheimer's disease.
abstract: There has been gratifying progress in the development of drugs for Alzheimer's disease (AD). Even though the current generation of medications, the cholinesterase inhibitors (CEIs), has produced only modest benefits, our concept of an "effective" therapy has matured considerably over this time. A less visible but equally important advance has been a quantum leap in expertise in clinical trial methodology. This chapter reviews the methodological underpinnings of clinical trials in AD: patient selection issues, key design issues, and an overview of currently available agents and the prospects for drugs of the future.
authors.affiliation: Department of Neurology, University of Minnesota Medical School, Minneapolis, MN.
authors.forename: D S
authors.initials: DS
authors.lastname: Knopman